104
Renal Failure Renal Failure and and Treatment Treatment Vicky Jefferson, RN, CNN Vicky Jefferson, RN, CNN Satellite Dialysis Satellite Dialysis

PPT version without narration

Embed Size (px)

Citation preview

Page 1: PPT version without narration

Renal Failure Renal Failure andand

TreatmentTreatmentVicky Jefferson, RN, CNNVicky Jefferson, RN, CNN

Satellite DialysisSatellite Dialysis

Page 2: PPT version without narration

Bones can break, muscles can Bones can break, muscles can atrophy, glands can loaf, even the atrophy, glands can loaf, even the brain can go to sleep without brain can go to sleep without immediate danger to survival. But immediate danger to survival. But -- should kidneys fail.... neither -- should kidneys fail.... neither bone, muscle, nor brain could carry bone, muscle, nor brain could carry on. on.

Homer Homer Smith, Ph.D.Smith, Ph.D.

Page 3: PPT version without narration

Renal HemodynamicsRenal Hemodynamics

Renal circulation receives 20 - 25 % Renal circulation receives 20 - 25 % of cardiac output under of cardiac output under normal normal physiologic conditions.physiologic conditions.

The bodies blood volume circulates The bodies blood volume circulates through the kidney every 6 minutes through the kidney every 6 minutes (12 times/hour).(12 times/hour).

Page 4: PPT version without narration

Functions of the KidneysFunctions of the Kidneys

Renin secretion Renin secretion and the regulation and the regulation of volume and of volume and composition of composition of extracellular fluid.extracellular fluid.

ExcretionExcretion Blood pressure Blood pressure

controlcontrol

Vitamin D Vitamin D activationactivation

Acid-base balance Acid-base balance regulation. regulation.

Erythropoietin Erythropoietin productionproduction

Urine formationUrine formation

Page 5: PPT version without narration

ReninRenin

Renin is important in the regulation of Renin is important in the regulation of blood pressure. blood pressure.

It is released from the granular cells of It is released from the granular cells of the efferent arteriole in response to the efferent arteriole in response to decreased arteriole blood pressure, renal decreased arteriole blood pressure, renal ischemia, extracellular fluid depletion, ischemia, extracellular fluid depletion, increased norepinephrine, and increased increased norepinephrine, and increased urinary Naurinary Na++ concentration. concentration.

Page 6: PPT version without narration

Blood Pressure Blood Pressure RegulationRegulation

4 mechanisms are involved4 mechanisms are involved Volume controlVolume control Aldosterone effectAldosterone effect Renin-angiotensin-aldosteroneRenin-angiotensin-aldosterone Renal prostaglandinRenal prostaglandin

Page 7: PPT version without narration

ProstaglandinProstaglandin

Prostoglandins (PGs)-Prostoglandins (PGs)- synthesized synthesized by most body tissues. In the kidney, by most body tissues. In the kidney, PGs are synthesized in the medulla and PGs are synthesized in the medulla and have a vasodilating action and promote have a vasodilating action and promote NaNa++ excretion. PGs counteract the excretion. PGs counteract the vasoconstrictor effect of angiotensin vasoconstrictor effect of angiotensin and norepinephrine. Renal PGs and norepinephrine. Renal PGs systemically lower blood pressure by systemically lower blood pressure by decreasing systemic vascular decreasing systemic vascular resistance.resistance.

Page 8: PPT version without narration

Vitamin DVitamin D

Acquired by the body through diet or Acquired by the body through diet or through synthesis by ultraviolet through synthesis by ultraviolet radiation on the cholesterol in the radiation on the cholesterol in the skin.skin.

The liver and the kidney make the The liver and the kidney make the vitamin active in the body. vitamin active in the body.

Page 9: PPT version without narration

ErythropoietinErythropoietin

Erythropoietin is produced and released Erythropoietin is produced and released by the kidneys in response to decreased by the kidneys in response to decreased oxygen tension in the renal blood supply oxygen tension in the renal blood supply that is created by the loss of red blood that is created by the loss of red blood cells. cells.

Erythropoietin stimulates the production Erythropoietin stimulates the production of RBCs in the bone marrow. of RBCs in the bone marrow.

Erythropoietin deficiency leads to Erythropoietin deficiency leads to anemia in renal failure.anemia in renal failure.

Page 10: PPT version without narration

RBC Synthesis & RBC Synthesis & MaturationMaturation

Kidney secrete Erythropoietin, it Kidney secrete Erythropoietin, it stimulates the bone marrow to stimulates the bone marrow to produce RBC’sproduce RBC’s

in oxygen delivery simulates releasein oxygen delivery simulates release in response the RBC count rises in 3 - 5 in response the RBC count rises in 3 - 5

daysdays speeds the maturation of RBC’sspeeds the maturation of RBC’s

Page 11: PPT version without narration

Acid Base BalanceAcid Base Balance

Kidneys regulate acid-base balance Kidneys regulate acid-base balance by stabilizing body fluid volume & by stabilizing body fluid volume & flow rate to enhance the flow rate to enhance the reabsorption or excretion of reabsorption or excretion of bicarbonate & hydrogen ionsbicarbonate & hydrogen ions

Page 12: PPT version without narration

Electrolyte RegulationElectrolyte Regulation

SodiumSodium PotassiumPotassium CalciumCalcium Need to Know:Need to Know: PhosphatePhosphate Normal ValuesNormal Values MagnesiumMagnesium FunctionsFunctions ChlorideChloride Factors affectFactors affect

Page 13: PPT version without narration

Excretion of Metabolic Excretion of Metabolic WasteWaste

Over 200 waste products excretedOver 200 waste products excreted Only 2 are used for clinical Only 2 are used for clinical

assessmentassessment BUNBUN CreatinineCreatinine

Page 14: PPT version without narration

Excretion of Metabolic Excretion of Metabolic WasteWaste

Over 200 waste products excretedOver 200 waste products excreted Only 2 are used for clinical Only 2 are used for clinical

assessmentassessment BUNBUN CreatinineCreatinine

Page 15: PPT version without narration

BUNBUN

Normal 8 - 20 mg/dlNormal 8 - 20 mg/dl Nitrogenous waste product of Nitrogenous waste product of

protein metabolismprotein metabolism Unreliable in measurement of renal Unreliable in measurement of renal

functionfunction Relevance is assessed in conjunction Relevance is assessed in conjunction

with Creatininewith Creatinine

Page 16: PPT version without narration

Factors Affecting BUNFactors Affecting BUN

Urine flowUrine flow low renal perfusionlow renal perfusion Volume depletionVolume depletion Metabolic rateMetabolic rate Protein metabolismProtein metabolism DrugsDrugs

Page 17: PPT version without narration

CreatinineCreatinine

A waste product of muscle A waste product of muscle metabolismmetabolism

Normal value 0.6 - 1.2 mg/dlNormal value 0.6 - 1.2 mg/dl 2 times normal = 50% damage 2 times normal = 50% damage 8 times normal = 75% damage8 times normal = 75% damage 10 times normal = 90% damage10 times normal = 90% damage Exception - severe muscular disease Exception - severe muscular disease

can greatly can greatly Creatinine levels Creatinine levels

Page 18: PPT version without narration

Diagnostic Tools for Diagnostic Tools for Assessing Renal FailureAssessing Renal Failure

Blood TestsBlood Tests BUN elevated (norm 10-20)BUN elevated (norm 10-20) Creatinine elevated (norm 0.6 - 1.2)Creatinine elevated (norm 0.6 - 1.2) K elevatedK elevated POPO4 4 elevatedelevated Ca decreasedCa decreased

UrinalysisUrinalysis Specific gravitySpecific gravity ProteinProtein Creatinine clearanceCreatinine clearance

Page 19: PPT version without narration

Diagnostic ToolsDiagnostic Tools

BiopsyBiopsy UltrasoundUltrasound X-RaysX-Rays

Page 20: PPT version without narration

Acute Renal Failure Acute Renal Failure (ARF)(ARF)

Sudden onset - hours to daysSudden onset - hours to days Often reversibleOften reversible Severe - 50% mortality rate overall; Severe - 50% mortality rate overall;

generally related to infectiongenerally related to infection. .

Page 21: PPT version without narration

Characteristics of ARFCharacteristics of ARF

Homeostatic functions affected mostHomeostatic functions affected most Electrolyte imbalancesElectrolyte imbalances Volume regulationVolume regulation Blood pressure controlBlood pressure control

Endocrine functions affected leaseEndocrine functions affected lease Require time to evolveRequire time to evolve

Renal size is preservedRenal size is preserved Evidence of acute illness or insult Evidence of acute illness or insult

existsexists

Page 22: PPT version without narration

Acute Renal Failure Acute Renal Failure (ARF)(ARF)

Sudden fall in glomerular filtration Sudden fall in glomerular filtration rate (GFR)rate (GFR) Retention of nitrogenous (BUN and Retention of nitrogenous (BUN and

creatinine) and other wastescreatinine) and other wastes Hours to daysHours to days

About 5% of all hospitalizationsAbout 5% of all hospitalizations About 20% of ICU admissionsAbout 20% of ICU admissions

Mortality 50 – 80%Mortality 50 – 80% Independent risk factor for death – 5x Independent risk factor for death – 5x

increase riskincrease risk

Page 23: PPT version without narration

Chronic Renal FailureChronic Renal Failure

Slow progressive renal disorder Slow progressive renal disorder related to nephron loss, occurring related to nephron loss, occurring over months to yearsover months to years

Culminates in End Stage Renal Culminates in End Stage Renal DiseaseDisease

Page 24: PPT version without narration

Characteristics of Characteristics of Chronic Renal FailureChronic Renal Failure

Cause & onset often unknownCause & onset often unknown Loss of function precedes lab Loss of function precedes lab

abnormalitiesabnormalities Lab abnormalities precede Lab abnormalities precede

symptomssymptoms Symptoms (usually) evolve in orderly Symptoms (usually) evolve in orderly

sequencesequence Renal size is usually decreasedRenal size is usually decreased

Page 25: PPT version without narration

Causes of Chronic Renal Causes of Chronic Renal FailureFailure

DiabetesDiabetes HypertensionHypertension GlomerulonephritisGlomerulonephritis Cystic disordersCystic disorders Developmental - CongenitalDevelopmental - Congenital Infectious DiseaseInfectious Disease

Page 26: PPT version without narration

Causes of Chronic Renal Causes of Chronic Renal Failure Failure

NeoplasmsNeoplasms Obstructive disordersObstructive disorders Autoimmune diseasesAutoimmune diseases

Lupus Lupus Hepatorenal failureHepatorenal failure SclerodermaScleroderma AmyloidosisAmyloidosis Drug toxicityDrug toxicity

Page 27: PPT version without narration

Glomerular Filtration RateGlomerular Filtration RateGFRGFR

24 hour urine for creatinine 24 hour urine for creatinine clearanceclearance

Can estimate creatinine clearance Can estimate creatinine clearance by:by:

140 – {age x weight (kg)}140 – {age x weight (kg)}

72 x serum creatinine72 x serum creatinine

Page 28: PPT version without narration

Stages of Chronic Renal Stages of Chronic Renal FailureFailure

Old SystemOld System Reduced Renal ReserveReduced Renal Reserve

Renal InsufficiencyRenal Insufficiency

End Stage Renal Disease (ESRD)End Stage Renal Disease (ESRD)

Page 29: PPT version without narration

Stages of Chronic Renal Stages of Chronic Renal FailureFailure

NKF Classification SystemNKF Classification System

Stage 1: Stage 1: GFR > 90 ml/min despite GFR > 90 ml/min despite kidney kidney damagedamage

Page 30: PPT version without narration

Stages of Chronic Renal Stages of Chronic Renal FailureFailure

NKF Classification SystemNKF Classification SystemStage 2:Stage 2: Mild reduction (GFR 60 – Mild reduction (GFR 60 –

89 89 ml/min)ml/min)

1. GFR of 60 may represent 1. GFR of 60 may represent 50% 50% loss in loss in function.function.

2. Parathyroid hormones 2. Parathyroid hormones starts to starts to increase. increase.

Page 31: PPT version without narration

During Stage 1 - 2During Stage 1 - 2

No symptomsNo symptoms

Serum creatinine doublesSerum creatinine doubles

Up to 50% nephron lossUp to 50% nephron loss

Page 32: PPT version without narration

Stages of Chronic Renal Stages of Chronic Renal FailureFailure

NKF Classification SystemNKF Classification SystemStage 3:Stage 3: Moderate reduction (GFR Moderate reduction (GFR

30 – 59 30 – 59 ml/min)ml/min)1. Calcium absorption 1. Calcium absorption

decreasesdecreases

2. Malnutrition onset2. Malnutrition onset

3. Anemia secondary to 3. Anemia secondary to Erythropoietin Erythropoietin deficiency deficiency

4. Left ventricular 4. Left ventricular hypertrophyhypertrophy

Page 33: PPT version without narration

Stages of Chronic Renal Stages of Chronic Renal FailureFailure

NKF Classification SystemNKF Classification SystemStage 4:Stage 4: Sever reduction (GFR 15 – Sever reduction (GFR 15 –

29 29 ml/min)ml/min)

1. Serum triglycerides 1. Serum triglycerides increaseincrease

2. Hyperphosphatemia2. Hyperphosphatemia

3. Metabolic acidosis3. Metabolic acidosis

4. Hyperkalemia4. Hyperkalemia

Page 34: PPT version without narration

During Stage 3 - 4During Stage 3 - 4

Signs and symptoms worsen if Signs and symptoms worsen if kidneys are stressedkidneys are stressed

Decreased ability to maintain Decreased ability to maintain homeostasishomeostasis

Page 35: PPT version without narration

During stages 3 - 4During stages 3 - 4

75% nephron loss 75% nephron loss Decreased: glomerular filtration Decreased: glomerular filtration

rate, solute clearance, ability to rate, solute clearance, ability to concentrate urine and hormone concentrate urine and hormone secretionsecretion

Symptoms: elevated BUN & Symptoms: elevated BUN & Creatinine, mild azotemia, anemiaCreatinine, mild azotemia, anemia

Page 36: PPT version without narration

Stages of Chronic Renal Stages of Chronic Renal FailureFailure

NKF Classification SystemNKF Classification System

Stage 5:Stage 5: Kidney failure (GFR < 15 Kidney failure (GFR < 15 ml/min)ml/min)

1. Azotemia1. Azotemia

Page 37: PPT version without narration

During Stage 5During Stage 5

Residual function < 15% of normalResidual function < 15% of normal Excretory, regulatory and hormonal Excretory, regulatory and hormonal

functions severely impaired. functions severely impaired. metabolic acidosismetabolic acidosis Marked increase in: BUN, Marked increase in: BUN,

Creatinine, PhosphorousCreatinine, Phosphorous Marked decrease in: Hemoglobin, Marked decrease in: Hemoglobin,

Hematocrit, CalciumHematocrit, Calcium Fluid overloadFluid overload

Page 38: PPT version without narration

During Stage 5During Stage 5

Uremic syndrome develops affecting Uremic syndrome develops affecting all body systemsall body systems can be diminished with early diagnosis can be diminished with early diagnosis

& treatment& treatment

Last stage of progressive CRFLast stage of progressive CRF Fatal if no treatmentFatal if no treatment

Page 39: PPT version without narration

What happens when the What happens when the kidneys don’t function kidneys don’t function

correctly?correctly?

Page 40: PPT version without narration

Manifestations of CRF -Manifestations of CRF -Nervous SystemNervous System

Mood swingsMood swings Impaired judgmentImpaired judgment Inability to concentrate and perform Inability to concentrate and perform

simple math functionssimple math functions Tremors, twitching, convulsionsTremors, twitching, convulsions Peripheral NeuropathyPeripheral Neuropathy

restless legsrestless legs foot dropfoot drop

Page 41: PPT version without narration

Manifestations of CRFManifestations of CRFSkinSkin

Pale, grayish-bronze colorPale, grayish-bronze color Dry scalyDry scaly Severe itchingSevere itching Bruise easilyBruise easily Uremic frostUremic frost

Page 42: PPT version without narration

Manifestations of CRFManifestations of CRFEyesEyes

Visual blurringVisual blurring Occasional blindnessOccasional blindness

Page 43: PPT version without narration

Manifestations of CRF Manifestations of CRF Fluid - Electrolyte - pHFluid - Electrolyte - pH

Volume expansion and fluid overloadVolume expansion and fluid overload Metabolic AcidosisMetabolic Acidosis Electrolyte ImbalancesElectrolyte Imbalances

HyperkalemiaHyperkalemia

Page 44: PPT version without narration

Manifestations of CRFManifestations of CRFGI TractGI Tract

Uremic fetorUremic fetor Anorexia, nausea, vomitingAnorexia, nausea, vomiting GI bleedingGI bleeding

Page 45: PPT version without narration

Manifestations of CRF Manifestations of CRF HematologicHematologic

AnemiaAnemia Platelet dysfunctionPlatelet dysfunction

Page 46: PPT version without narration

Manifestations of CRF Manifestations of CRF MusculoskeletalMusculoskeletal

Muscle crampsMuscle cramps Soft tissue calcificationsSoft tissue calcifications WeaknessWeakness Related to calcium phosphorous Related to calcium phosphorous

imbalancesimbalances

Page 47: PPT version without narration

Calcium-Phosphorous Calcium-Phosphorous BalanceBalance

Page 48: PPT version without narration

Manifestations of CRFManifestations of CRFHeart - LungsHeart - Lungs

HypertensionHypertension Congestive heart failureCongestive heart failure PericarditisPericarditis Pulmonary edemaPulmonary edema Pleural effusionsPleural effusions

Page 49: PPT version without narration

Manifestations of CRF Manifestations of CRF Endocrine - MetabolicEndocrine - Metabolic

Erythropoietin production decreasedErythropoietin production decreased HypothyroidismHypothyroidism Insulin resistanceInsulin resistance Growth hormone decreasedGrowth hormone decreased Gonadal dysfunctionGonadal dysfunction Parathyroid hormone and Vitamin DParathyroid hormone and Vitamin D33

HyperlipidemiaHyperlipidemia

Page 50: PPT version without narration

Treatment OptionsTreatment Options

HemodialysisHemodialysis Peritoneal DialysisPeritoneal Dialysis TransplantTransplant NothingNothing

Page 51: PPT version without narration

HemodialysisHemodialysis

Removal of soluble substances Removal of soluble substances and and water from the blood by water from the blood by diffusion diffusion through a semi-through a semi-permeable membrane. permeable membrane.

Page 52: PPT version without narration

HistoryHistory

Early animal experiments began Early animal experiments began 19131913

1st human dialysis 1940 by Dutch 1st human dialysis 1940 by Dutch physician Willem Kolff (2 of 17 physician Willem Kolff (2 of 17 patients survived)patients survived)

Considered experimental through Considered experimental through 1950’s, No intermittent blood 1950’s, No intermittent blood access; for acute renal failure only. access; for acute renal failure only.

Page 53: PPT version without narration

History cont’dHistory cont’d

1960 Dr. Scribner developed 1960 Dr. Scribner developed Scribner ShuntScribner Shunt

1960’s Machines expensive, scarce, 1960’s Machines expensive, scarce, no funding.no funding.

““Death Panels” panels within Death Panels” panels within community decided who got to community decided who got to dialyze.dialyze.

Page 54: PPT version without narration

Hemodialysis ProcessHemodialysis Process

Blood removed from patient into the Blood removed from patient into the extracorporeal circuit. extracorporeal circuit.

Diffusion and ultrafiltration take Diffusion and ultrafiltration take place in the dialyzer. place in the dialyzer.

Cleaned blood returned to patient. Cleaned blood returned to patient.

Page 55: PPT version without narration

Extracorporeal CircuitExtracorporeal Circuit

Page 56: PPT version without narration

How Hemodialysis How Hemodialysis WorksWorks

Page 57: PPT version without narration

Vascular AccessVascular Access

Arterio-venous shunt (Scribner Arterio-venous shunt (Scribner External Shunt)External Shunt)

Arterio-venous (AV) FistulaArterio-venous (AV) Fistula PTFE GraftPTFE Graft Temporary cathetersTemporary catheters ““Permanent” cathetersPermanent” catheters

Page 58: PPT version without narration

Scribner ShuntScribner Shunt

External- one end External- one end into artery, one into into artery, one into vein. vein.

AdvantagesAdvantages place at bedsideplace at bedside use immediatelyuse immediately

DisadvantagesDisadvantages infectioninfection skin erosionskin erosion accidental separation accidental separation limits use of limits use of

extremityextremity

Page 59: PPT version without narration

Arterio-venous (AV) Arterio-venous (AV) FistulaFistula

Primary FistulaPrimary Fistula Patients own artery and vein surgically Patients own artery and vein surgically

anastomosed.anastomosed. AdvantagesAdvantages

patients own veinpatients own vein longevitylongevity low infection and thrombosis rateslow infection and thrombosis rates

DisadvantagesDisadvantages long time to mature, 1- 6 monthslong time to mature, 1- 6 months ““steal” syndromesteal” syndrome requires needle sticksrequires needle sticks

Page 60: PPT version without narration

PTFE PTFE (Polytetraflourethylene) (Polytetraflourethylene)

GraftGraft Synthetic “vessel” anastomosed into an artery and Synthetic “vessel” anastomosed into an artery and

vein.vein. AdvantagesAdvantages

for people with inadequate vesselsfor people with inadequate vessels can be used in 7-14 dayscan be used in 7-14 days prominent vesselsprominent vessels

DisadvantagesDisadvantages clots easilyclots easily ““steal” syndrome more frequentsteal” syndrome more frequent requires needle sticksrequires needle sticks infection may necessitate removal of graftinfection may necessitate removal of graft

Page 61: PPT version without narration

Temporary CathetersTemporary Catheters

Dual lumen catheter placed into a central Dual lumen catheter placed into a central vein-subclavian, jugular or femoral.vein-subclavian, jugular or femoral.

AdvantagesAdvantages immediate useimmediate use no needle sticksno needle sticks

DisadvantagesDisadvantages high incidence of infectionhigh incidence of infection subclavian vein stenosissubclavian vein stenosis poor flow-inadequate dialysispoor flow-inadequate dialysis clottingclotting

Page 62: PPT version without narration

Cuffed Tunneled Cuffed Tunneled CathetersCatheters

Dual lumen catheter with Dacron Dual lumen catheter with Dacron cuff surgically tunneled into cuff surgically tunneled into subclavian, jugular or femoral subclavian, jugular or femoral vein.vein.

AdvantagesAdvantages immediate useimmediate use can be used for patients that can be used for patients that

can have no other permanent can have no other permanent accessaccess

no needle sticksno needle sticks DisadvantagesDisadvantages

high incidence of infectionhigh incidence of infection poor flows result in inadequate poor flows result in inadequate

dialysisdialysis clottingclotting

Page 63: PPT version without narration

Care of Vascular AccessCare of Vascular Access

NONO BP’s, needle sticks to arm with BP’s, needle sticks to arm with vascular access. This includes finger vascular access. This includes finger sticks.sticks.

Place ID bands on other arm Place ID bands on other arm whenever possible.whenever possible.

Palpate thrill and listen for bruit.Palpate thrill and listen for bruit. Teach patient nothing constrictive, Teach patient nothing constrictive,

feel for thrill.feel for thrill.

Page 64: PPT version without narration

Complications of Complications of HemodialysisHemodialysis

During dialysisDuring dialysis Fluid and electrolyte related Fluid and electrolyte related

hypotensionhypotension CardiovascularCardiovascular

arrythmiasarrythmias Associated with the extracorporeal circuitAssociated with the extracorporeal circuit

exsanguinationexsanguination NeurologicNeurologic

seizuresseizures otherother

feverfever

Page 65: PPT version without narration

Complications of Complications of Hemodialysis cont’dHemodialysis cont’d

Between treatmentsBetween treatments Hypertension/HypotensionHypertension/Hypotension EdemaEdema Pulmonary edemaPulmonary edema HyperkalemiaHyperkalemia BleedingBleeding Clotting of accessClotting of access

Page 66: PPT version without narration

Complications of Complications of Hemodialysis cont’dHemodialysis cont’d

Long termLong term MetabolicMetabolic

hyperparathyroidismhyperparathyroidism diabetic complicationsdiabetic complications

CardiovascularCardiovascular CHFCHF AV access failureAV access failure

RespiratoryRespiratory pulmonary edemapulmonary edema

NeuromuscularNeuromuscular neuropathyneuropathy

Page 67: PPT version without narration

Complications of Complications of HemodialysisHemodialysis

cont’dcont’d Long term cont’dLong term cont’d

HematologicHematologic anemiaanemia

GIGI bleedingbleeding

dermatologicdermatologic calcium phosphorous depositscalcium phosphorous deposits

RheumatologicRheumatologic amyloid depositsamyloid deposits

Page 68: PPT version without narration

Complications of Complications of Hemodialysis cont’dHemodialysis cont’d

Long term cont’dLong term cont’d GenitourinaryGenitourinary

infectioninfection sexual dysfunctionsexual dysfunction

PsychiatricPsychiatric depressiondepression

InfectionInfection bloodborne pathogensbloodborne pathogens

Page 69: PPT version without narration

Dietary Restrictions on Dietary Restrictions on HemodialysisHemodialysis

Fluid restrictionsFluid restrictions Phosphorous restrictionsPhosphorous restrictions Potassium restrictionsPotassium restrictions Sodium restrictionsSodium restrictions Protein to maintain nitrogen balanceProtein to maintain nitrogen balance

too high - waste productstoo high - waste products too low - decreased albumin, increased too low - decreased albumin, increased

mortalitymortality Calories to maintain or reach ideal weightCalories to maintain or reach ideal weight

Page 70: PPT version without narration

Peritoneal DialysisPeritoneal Dialysis

Removal of soluble substances and Removal of soluble substances and water from the blood by diffusion water from the blood by diffusion through a semi-permeable through a semi-permeable membrane that is intracorporeal membrane that is intracorporeal (inside the body).(inside the body).

Page 71: PPT version without narration

Types of Peritoneal Types of Peritoneal DialysisDialysis

CAPD: CAPD: Continuous ambulatory peritoneal Continuous ambulatory peritoneal dialysisdialysis

CCPDCCPD: Continuous cycling peritoneal : Continuous cycling peritoneal dialysisdialysis

IPD: IPD: Intermittent peritoneal dialysisIntermittent peritoneal dialysis

Page 72: PPT version without narration

CAPDCAPD

Catheter into peritoneal cavityCatheter into peritoneal cavity Exchanges 4 - 5 times per dayExchanges 4 - 5 times per day Treatment 24 hours; 7 days a weekTreatment 24 hours; 7 days a week Solution remains in peritoneal cavity Solution remains in peritoneal cavity

except during drain timeexcept during drain time Independent treatmentIndependent treatment

Page 73: PPT version without narration
Page 74: PPT version without narration

Phases of A Peritoneal Phases of A Peritoneal Dialysis ExchangeDialysis Exchange

Fill: fluid infused into peritoneal Fill: fluid infused into peritoneal cavitycavity

Dwell: time fluid remains in Dwell: time fluid remains in peritoneal cavityperitoneal cavity

Drain: time fluid drains from Drain: time fluid drains from peritoneal cavityperitoneal cavity

Page 75: PPT version without narration

Complications of Complications of Peritoneal DialysisPeritoneal Dialysis

InfectionInfection peritonitisperitonitis tunnel infectionstunnel infections catheter exit site catheter exit site

HypervolemiaHypervolemia hypertensionhypertension pulmonary edemapulmonary edema

HypovolemiaHypovolemia hypotensionhypotension

HyperglycemiaHyperglycemia MalnutritionMalnutrition

Page 76: PPT version without narration

Complications of Complications of Peritoneal Dialysis cont’dPeritoneal Dialysis cont’d ObesityObesity HypokalemiaHypokalemia HerniaHernia Cuff erosionCuff erosion

Page 77: PPT version without narration

Advantages of CAPDAdvantages of CAPD

Independence for patientIndependence for patient No needle sticksNo needle sticks Better blood pressure controlBetter blood pressure control Some diabetics add insulin to solutionSome diabetics add insulin to solution Fewer dietary restrictionsFewer dietary restrictions

protein loses in dialysateprotein loses in dialysate generally need increased potassiumgenerally need increased potassium less fluid restrictionsless fluid restrictions

Page 78: PPT version without narration

Peritoneal Catheter Exit Peritoneal Catheter Exit SiteSite

Page 79: PPT version without narration
Page 80: PPT version without narration

Medications Common to Medications Common to Dialysis PatientsDialysis Patients

Vitamins - water solubleVitamins - water soluble Phosphate binder - (Phoslo, Renagel, Phosphate binder - (Phoslo, Renagel,

Calcium, Aluminum hydroxide) Give Calcium, Aluminum hydroxide) Give with mealswith meals

Iron Supplements - don’t give with Iron Supplements - don’t give with phosphate binder or calciumphosphate binder or calcium

Antihypertensives - hold prior to Antihypertensives - hold prior to dialysisdialysis

Page 81: PPT version without narration

Medications Common to Medications Common to Dialysis Patients cont’dDialysis Patients cont’d

ErythropoietinErythropoietin Calcium Supplements - Calcium Supplements - BetweenBetween

meals, meals, notnot with iron with iron Activated Vitamin DActivated Vitamin D3 3 - aids in - aids in

calcium absorptioncalcium absorption Antibiotics - hold dose prior to Antibiotics - hold dose prior to

dialysis if it dialyzes outdialysis if it dialyzes out

Page 82: PPT version without narration

MedicationsMedications

Many drugs or their metabolites are Many drugs or their metabolites are excreted by the kidneyexcreted by the kidney

Dosages - many change when used Dosages - many change when used in renal failure patientsin renal failure patients

Dialyzability - many removed by Dialyzability - many removed by dialysis varies between HD and PDdialysis varies between HD and PD

Page 83: PPT version without narration

Patient EducationPatient Education

Alleviate fearAlleviate fear Dialysis processDialysis process Fistula/catheter careFistula/catheter care Diet and fluid restrictionsDiet and fluid restrictions MedicationMedication Diabetic teachingDiabetic teaching

Page 84: PPT version without narration

Case StudyCase Study

A 48 year old female with a history of A 48 year old female with a history of uncontrolled diabetes presents to uncontrolled diabetes presents to the ER. Her chief complaints are the ER. Her chief complaints are nausea, vomiting and fatigue.nausea, vomiting and fatigue.

Lab: Lab: BUN 100; Creatinine 10; H&H BUN 100; Creatinine 10; H&H 7.0/21.4; 7.0/21.4;

KK+ + 6.0, PO 6.0, PO4 4 5.5; Ca5.5; Ca++ ++ 7.57.5

What do you suspect? How would she What do you suspect? How would she possibly be treated?possibly be treated?

Page 85: PPT version without narration

TransplantationTransplantation

TreatmentTreatment not not curecure

Page 86: PPT version without narration

Kidney Awaiting Kidney Awaiting TransplantTransplant

Page 87: PPT version without narration
Page 88: PPT version without narration

Transplanted KidneyTransplanted Kidney

Page 89: PPT version without narration

AdvantagesAdvantages

Restoration of “normal” renal Restoration of “normal” renal functionfunction

Freedom from dialysisFreedom from dialysis Return to “normal” lifeReturn to “normal” life

Page 90: PPT version without narration

DisadvantagesDisadvantages

Life long medicationsLife long medications Multiple side effects from Multiple side effects from

medicationmedication Increased risk of tumorIncreased risk of tumor Increased risk of infectionIncreased risk of infection Major surgeryMajor surgery

Page 91: PPT version without narration

Care of the RecipientCare of the Recipient

Major surgery with general Major surgery with general anesthesiaanesthesia

Assessment of renal functionAssessment of renal function Assessment of fluid and electrolyte Assessment of fluid and electrolyte

balancebalance Prevention of infectionPrevention of infection Prevention and management of Prevention and management of

rejectionrejection

Page 92: PPT version without narration

FunctionFunction

ATN? (acute tubular necrosis) ATN? (acute tubular necrosis) 50% experience50% experience

Urine output >100 <500 cc/hrUrine output >100 <500 cc/hr BUN, creatinine, creatinine clearanceBUN, creatinine, creatinine clearance Fluid BalanceFluid Balance UltrasoundUltrasound Renal scansRenal scans Renal biopsyRenal biopsy

Page 93: PPT version without narration

Fluid & Electrolyte Fluid & Electrolyte BalanceBalance

Accurate I & OAccurate I & O CRITICAL TO AVOID DEHYDRATIONCRITICAL TO AVOID DEHYDRATION Output normal - >100 <500 cc/hr, could Output normal - >100 <500 cc/hr, could

be 1-2 L/hrbe 1-2 L/hr Potential for volume overload/deficitPotential for volume overload/deficit

Daily weightsDaily weights Hyper/Hypokalemia potentialHyper/Hypokalemia potential HyponatremiaHyponatremia HyperglycemiaHyperglycemia

Page 94: PPT version without narration

Prevention of InfectionPrevention of Infection

Major complication of Major complication of transplantation due to transplantation due to immunosuppressionimmunosuppression

HANDWASHINGHANDWASHING Crowds, KidsCrowds, Kids Patient EducationPatient Education

Page 95: PPT version without narration

RejectionRejection

Hyperacute - preformed antibodies Hyperacute - preformed antibodies to donor antigento donor antigen function ceases within 24 hoursfunction ceases within 24 hours Rx = removalRx = removal

Accelerated - same as hyperacute Accelerated - same as hyperacute but slower, 1st week to monthbut slower, 1st week to month Rx = removalRx = removal

Page 96: PPT version without narration

Rejection cont’dRejection cont’d

Acute - generally after 1st 10 days to Acute - generally after 1st 10 days to end of 2nd monthend of 2nd month 50% experience50% experience must differentiate between rejection must differentiate between rejection

and cyclosporine toxicityand cyclosporine toxicity Rx = steroids, monoclonal (OKTRx = steroids, monoclonal (OKT33), or ), or

polyclonal (HTG) antibodiespolyclonal (HTG) antibodies

Page 97: PPT version without narration

Rejection cont’dRejection cont’d

Chronic - gradual process of graft Chronic - gradual process of graft dysfunctiondysfunction Repeated rejection episodes that have Repeated rejection episodes that have

not been completely resolved with not been completely resolved with treatmenttreatment

Rx = return to dialysis or re-Rx = return to dialysis or re-transplantationtransplantation

Page 98: PPT version without narration

Immunosuppressant Immunosuppressant DrugsDrugs

PrednisonePrednisone Prevents infiltration of T lymphocytesPrevents infiltration of T lymphocytes

Side effectsSide effects cushnoid changescushnoid changes Avascular NecrosisAvascular Necrosis GI disturbancesGI disturbances DiabetesDiabetes infectioninfection risk of tumorrisk of tumor

Page 99: PPT version without narration

Immunosuppressant Immunosuppressant Drugs cont’dDrugs cont’d

Azathioprine (Imuran)Azathioprine (Imuran) Prevents rapid growing lymphocytesPrevents rapid growing lymphocytes

Side EffectsSide Effects bone marrow toxicitybone marrow toxicity hepatotoxicityhepatotoxicity hair losshair loss infectioninfection risk of tumorrisk of tumor

Page 100: PPT version without narration

Immunosuppressant Immunosuppressant Drugs cont’dDrugs cont’d

CyclosporinCyclosporin Interferes with production of Interferes with production of

interleukin 2 which is necessary for interleukin 2 which is necessary for growth and activation of T lymphocytes.growth and activation of T lymphocytes.

• Side EffectsSide Effects– NephrotoxicityNephrotoxicity– HTNHTN– HepatotoxicityHepatotoxicity– Gingival hyperplasiaGingival hyperplasia– InfectionInfection

Page 101: PPT version without narration

Immunosuppressant Immunosuppressant Drugs cont’dDrugs cont’d

Cytoxan - in place of Imuran less Cytoxan - in place of Imuran less toxictoxic

FK506 - 100 x more potent than FK506 - 100 x more potent than CyclosporinCyclosporin

PrografPrograf CellceptCellcept

Page 102: PPT version without narration

Immunosuppressant Immunosuppressant Drugs cont’dDrugs cont’d

OKTOKT33 - monoclonal antibody used to treat rejection - monoclonal antibody used to treat rejection or induce immunosuppressionor induce immunosuppression decreases CDdecreases CD3 3 cells within 1 hour cells within 1 hour

Side effectsSide effects anaphylaxisanaphylaxis fever/chillsfever/chills pulmonary edemapulmonary edema risk of infectionrisk of infection tumorstumors

1st dose reaction expected & wanted, pre-treat 1st dose reaction expected & wanted, pre-treat with Benadryl, Tylenol, Solumedrolwith Benadryl, Tylenol, Solumedrol

Page 103: PPT version without narration

Immunosuppressant Immunosuppressant Drugs cont’dDrugs cont’d

Atgam - polyclonal antibody used to treat Atgam - polyclonal antibody used to treat rejection or induce immunosuppressionrejection or induce immunosuppression decreased number of T lymphocytesdecreased number of T lymphocytes

Side effectsSide effects anaphylaxisanaphylaxis fever chillsfever chills leukopenialeukopenia thrombocytopeniathrombocytopenia risk of infectionrisk of infection tumortumor

Page 104: PPT version without narration

Patient EducationPatient Education

Signs of infectionSigns of infection Prevention of infectionPrevention of infection Signs of rejectionSigns of rejection

decreased urine outputdecreased urine output increased weight gainincreased weight gain tenderness over kidneytenderness over kidney fever > 100 degrees Ffever > 100 degrees F

MedicationsMedications time, dose, side effectstime, dose, side effects